We wanted to determine how NAT10 regulates NFE2L3 to promote the progression of ccRCC, and since NFE2L3 is a transcription factor [19], we performed ChIP-seq for NFE2L3, as well as RNA-seq in 786-O cells with a NFE2L3 knockdown and control 786-O cells. This evidence concerns the gene NFE2L3 and nonpapillary renal cell carcinoma.